In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $78.00. Mohit Bansal has
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $78.00. Mohit Bansal has
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Chris Schott from J.P. Morgan maintained a Buy rating on the
Unusual total active option classes on open include: KB Home (KBH), iShares South Korea (EWY), Gilead (GILD), Pan American Silver (PAAS), BlackBerry (BB), Plains All American (PAA), Taiwan Semi (TSM),
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Gilead Sciences (GILD – Research Report) and Agios Pharma (AGIO – Research Report).
Alnylam Pharma (ALNY)
In a report issued on April 4, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma, with a price target of $235.00. The company’s shares closed last Monday at $156.04, close to its 52-week low of $143.52.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $223.33, representing a 44.4% upside. In a report issued on March 22, Canaccord Genuity also maintained a Buy rating on the stock with a $283.00 price target.
See the top stocks recommended by analysts >>
Gilead Sciences (GILD)
In a report issued on April 4, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $76.00. The company’s shares closed last Monday at $69.42, close to its 52-week low of $68.54.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $85.89.
Agios Pharma (AGIO)
RBC Capital analyst Gregory Renza maintained a Buy rating on Agios Pharma on April 4 and set a price target of $42.00. The company’s shares closed last Monday at $27.70.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Agios Pharma is a Strong Buy with an average price target of $42.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
Welcome to “Fly Insider,” The Fly’s weekly recap of notable insider stock transactions. NOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from April 1 through April 5